Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma

Amy R. Deipolyi, Rahmi Oklu, Shehab Al-Ansari, Andrew X. Zhu, Lipika Goyal, Suvranu Ganguli

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose To compare the safety and efficacy of using 70-150 μm drug-eluting beads (DEBs) (LC BeadM1; Biocompatibles UK Ltd, Farnham, Surrey, United Kingdom) in addition to 100-300 μm DEBs with 100-300 μm DEBs alone in transarterial chemoembolization for treatment of hepatocellular carcinoma (HCC). Materials and Methods A cohort of patients with HCC who underwent transarterial chemoembolization with two vials of 100-300 μm DEBs (group 1, 55 procedures among 42 patients, 33 men, average Model for End-Stage Liver Disease score 10 ± 0.6, 67% Child-Pugh A, 33% Child-Pugh B) was retrospectively compared with a cohort of patients who underwent transarterial chemoembolization with one vial of 70-150 μm DEBs followed by one vial of 100-300 μm DEBs (group 2, 51 procedures among 42 patients, 29 men, average Model for End-Stage Liver Disease score 9 ± 0.6, 73% Child-Pugh A, 27% Child-Pugh B) in regard to adverse events and response on 1-month follow-up imaging using modified Response Evaluation Criteria In Solid Tumors criteria. Results There was no difference in 1-month imaging response (P =.3). Patients in group 2 were readmitted more often within 1 month for hepatobiliary adverse events (group 2, 25%; group 1, 9%; P <.0001), including ascites, gastrointestinal hemorrhage, biliary dilatation, and cholecystitis. Conclusions Despite similar efficacy based on short-term follow-up imaging, transarterial chemoembolization with smaller DEBs (70-150 μm) followed by larger DEBs (100-300 μm) may cause more hepatobiliary adverse events.

Original languageEnglish (US)
Pages (from-to)516-522
Number of pages7
JournalJournal of Vascular and Interventional Radiology
Volume26
Issue number4
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Safety
Pharmaceutical Preparations
End Stage Liver Disease
Cholecystitis
Gastrointestinal Hemorrhage
Ascites
Dilatation

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. / Deipolyi, Amy R.; Oklu, Rahmi; Al-Ansari, Shehab; Zhu, Andrew X.; Goyal, Lipika; Ganguli, Suvranu.

In: Journal of Vascular and Interventional Radiology, Vol. 26, No. 4, 01.04.2015, p. 516-522.

Research output: Contribution to journalArticle

Deipolyi, Amy R. ; Oklu, Rahmi ; Al-Ansari, Shehab ; Zhu, Andrew X. ; Goyal, Lipika ; Ganguli, Suvranu. / Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. In: Journal of Vascular and Interventional Radiology. 2015 ; Vol. 26, No. 4. pp. 516-522.
@article{7591d13b9c4c4f088aa68f53bcf3e9c6,
title = "Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma",
abstract = "Purpose To compare the safety and efficacy of using 70-150 μm drug-eluting beads (DEBs) (LC BeadM1; Biocompatibles UK Ltd, Farnham, Surrey, United Kingdom) in addition to 100-300 μm DEBs with 100-300 μm DEBs alone in transarterial chemoembolization for treatment of hepatocellular carcinoma (HCC). Materials and Methods A cohort of patients with HCC who underwent transarterial chemoembolization with two vials of 100-300 μm DEBs (group 1, 55 procedures among 42 patients, 33 men, average Model for End-Stage Liver Disease score 10 ± 0.6, 67{\%} Child-Pugh A, 33{\%} Child-Pugh B) was retrospectively compared with a cohort of patients who underwent transarterial chemoembolization with one vial of 70-150 μm DEBs followed by one vial of 100-300 μm DEBs (group 2, 51 procedures among 42 patients, 29 men, average Model for End-Stage Liver Disease score 9 ± 0.6, 73{\%} Child-Pugh A, 27{\%} Child-Pugh B) in regard to adverse events and response on 1-month follow-up imaging using modified Response Evaluation Criteria In Solid Tumors criteria. Results There was no difference in 1-month imaging response (P =.3). Patients in group 2 were readmitted more often within 1 month for hepatobiliary adverse events (group 2, 25{\%}; group 1, 9{\%}; P <.0001), including ascites, gastrointestinal hemorrhage, biliary dilatation, and cholecystitis. Conclusions Despite similar efficacy based on short-term follow-up imaging, transarterial chemoembolization with smaller DEBs (70-150 μm) followed by larger DEBs (100-300 μm) may cause more hepatobiliary adverse events.",
author = "Deipolyi, {Amy R.} and Rahmi Oklu and Shehab Al-Ansari and Zhu, {Andrew X.} and Lipika Goyal and Suvranu Ganguli",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.jvir.2014.12.020",
language = "English (US)",
volume = "26",
pages = "516--522",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma

AU - Deipolyi, Amy R.

AU - Oklu, Rahmi

AU - Al-Ansari, Shehab

AU - Zhu, Andrew X.

AU - Goyal, Lipika

AU - Ganguli, Suvranu

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Purpose To compare the safety and efficacy of using 70-150 μm drug-eluting beads (DEBs) (LC BeadM1; Biocompatibles UK Ltd, Farnham, Surrey, United Kingdom) in addition to 100-300 μm DEBs with 100-300 μm DEBs alone in transarterial chemoembolization for treatment of hepatocellular carcinoma (HCC). Materials and Methods A cohort of patients with HCC who underwent transarterial chemoembolization with two vials of 100-300 μm DEBs (group 1, 55 procedures among 42 patients, 33 men, average Model for End-Stage Liver Disease score 10 ± 0.6, 67% Child-Pugh A, 33% Child-Pugh B) was retrospectively compared with a cohort of patients who underwent transarterial chemoembolization with one vial of 70-150 μm DEBs followed by one vial of 100-300 μm DEBs (group 2, 51 procedures among 42 patients, 29 men, average Model for End-Stage Liver Disease score 9 ± 0.6, 73% Child-Pugh A, 27% Child-Pugh B) in regard to adverse events and response on 1-month follow-up imaging using modified Response Evaluation Criteria In Solid Tumors criteria. Results There was no difference in 1-month imaging response (P =.3). Patients in group 2 were readmitted more often within 1 month for hepatobiliary adverse events (group 2, 25%; group 1, 9%; P <.0001), including ascites, gastrointestinal hemorrhage, biliary dilatation, and cholecystitis. Conclusions Despite similar efficacy based on short-term follow-up imaging, transarterial chemoembolization with smaller DEBs (70-150 μm) followed by larger DEBs (100-300 μm) may cause more hepatobiliary adverse events.

AB - Purpose To compare the safety and efficacy of using 70-150 μm drug-eluting beads (DEBs) (LC BeadM1; Biocompatibles UK Ltd, Farnham, Surrey, United Kingdom) in addition to 100-300 μm DEBs with 100-300 μm DEBs alone in transarterial chemoembolization for treatment of hepatocellular carcinoma (HCC). Materials and Methods A cohort of patients with HCC who underwent transarterial chemoembolization with two vials of 100-300 μm DEBs (group 1, 55 procedures among 42 patients, 33 men, average Model for End-Stage Liver Disease score 10 ± 0.6, 67% Child-Pugh A, 33% Child-Pugh B) was retrospectively compared with a cohort of patients who underwent transarterial chemoembolization with one vial of 70-150 μm DEBs followed by one vial of 100-300 μm DEBs (group 2, 51 procedures among 42 patients, 29 men, average Model for End-Stage Liver Disease score 9 ± 0.6, 73% Child-Pugh A, 27% Child-Pugh B) in regard to adverse events and response on 1-month follow-up imaging using modified Response Evaluation Criteria In Solid Tumors criteria. Results There was no difference in 1-month imaging response (P =.3). Patients in group 2 were readmitted more often within 1 month for hepatobiliary adverse events (group 2, 25%; group 1, 9%; P <.0001), including ascites, gastrointestinal hemorrhage, biliary dilatation, and cholecystitis. Conclusions Despite similar efficacy based on short-term follow-up imaging, transarterial chemoembolization with smaller DEBs (70-150 μm) followed by larger DEBs (100-300 μm) may cause more hepatobiliary adverse events.

UR - http://www.scopus.com/inward/record.url?scp=84925400155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925400155&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2014.12.020

DO - 10.1016/j.jvir.2014.12.020

M3 - Article

C2 - 25704226

AN - SCOPUS:84925400155

VL - 26

SP - 516

EP - 522

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 4

ER -